HC Wainwright reiterated their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a report published on Monday morning, Benzinga reports. They currently have a $8.00 price objective on the stock.
InflaRx Stock Performance
InflaRx stock opened at $1.60 on Monday. The business’s 50-day simple moving average is $1.45 and its two-hundred day simple moving average is $1.55. The company has a market cap of $94.21 million, a PE ratio of -2.05 and a beta of 1.20. InflaRx has a fifty-two week low of $1.14 and a fifty-two week high of $4.61.
InflaRx (NASDAQ:IFRX – Get Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.05. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $1.76 million. As a group, analysts predict that InflaRx will post -0.81 EPS for the current fiscal year.
Institutional Trading of InflaRx
About InflaRx
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
Further Reading
- Five stocks we like better than InflaRx
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- What is the S&P 500 and How It is Distinct from Other Indexes
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- How to Invest in Insurance Companies: A Guide
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.